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 APOL1 variants in HIV-associated 
nephropathy: just one piece of 
the puzzle 
 Thomas  Hays 1 and  Christina M.  Wyatt 1 
 Considerable attention has been focused on how the  APOL1 / MYH9 
locus determines susceptibility to focal segmental glomerulosclerosis, 
including HIV-associated nephropathy (HIVAN). Atta and colleagues 
found that homozygosity for  APOL1 risk alleles was associated with 
many, but not all, HIVAN cases, and that  APOL1 variation failed to 
predict characteristics of disease. Their work gives important impetus 
to identify other genetic and environmental factors that may provide 
a  ‘ second hit ’ linking HIV infection to HIVAN. 
 Kidney International (2012)  82, 259 – 260.  doi: 10.1038/ki.2012.129 
 In 2008, Kopp and colleagues demon-
strated that single-nucleotide polymor-
phisms (SNPs) in a locus on chromosome 
22 determine much of the susceptibility of 
African Americans to focal segmental 
glomerulosclerosis (FSGS), a disease 
known to disproportionately affect 
blacks. 1 Although the identifi ed genetic 
locus included more than 30 genes, early 
investigation focused on  MYH9 , in part 
because of the established connection to 
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a rare mendelian disease with a glomeru-
lar phenotype. A concurrent publication 
reported a similar association with non-
diabetic end-stage renal disease, providing 
further support for the importance of this 
genetic locus in determining kidney dis-
ease susceptibility. 2 Although these stud-
ies confi rmed the strong genetic basis for 
ethnic disparities in kidney disease, they 
did not provide any insight into potential 
mechanisms, as the implicated SNPs 
were all in non-coding regions of  MYH9 . 
More recently, Genovese and colleagues 
reported that variants in the neighboring 
gene  APOL1 (see Figure 1) are more 
strongly associated with FSGS, suggesting 
that the closely linked  MYH9 SNPs are 
only sentinel markers. 3 Th e  APOL1 risk 
alleles were also shown to enhance the 
protein ’ s ability to lyse trypanosomes, the 
parasites responsible for African sleeping 
sickness, suggesting a potential mecha-
nism for the increased frequency in 
African ancestral populations. 
 Although the association of  APOL1 
variants with FSGS has been replicated in 
independent analyses, 4  APOL1 has no 
known role in the kidney. In addition, 
 MYH9 SNPs have also been associated 
with chronic kidney disease in European 
Americans lacking the  APOL1 risk alle-
les, 5 and mechanistic studies continue to 
support a possible role for  MYH9 in the 
pathogenesis of FSGS.  MYH9 ablation in 
podocytes was shown to predispose mice 
to adriamycin nephropathy, a drug-
induced model of FSGS. 6 More recently, 
 MYH9 was found to be downregulated 
in the glomeruli of patients with HIV-
associated nephropathy (HIVAN), 
a unique form of secondary FSGS that 
almost exclusively affects people of 
African descent. 7 Th ese studies suggest 
that both  APOL1 and  MYH9 may contrib-
ute to the complex pathogenesis of FSGS, 
although polymorphisms in  APOL1 have 
a more prominent infl uence on disease 
susceptibility. 3,8 
 Atta and colleagues 9 (this issue) 
consider the clinical implications of 
 APOL1 variants in a cohort of patients 
with biopsy-proven HIVAN. Among 60 
subjects with biopsy-defi ned HIVAN who 
were genotyped for the  APOL1 G1 and G2 
polymorphisms, more than one-third had 
zero or one risk allele. When these sub-
jects were compared with subjects with 
two risk alleles,  APOL1 variation was not 
associated with the histologic pattern of 
injury or with renal survival. Th e latter 
fi nding is in contrast to previous reports 
in patients with idiopathic FSGS and in 
HIV-positive patients with other forms of 
kidney disease, 4,10 but it is consistent with 
a smaller study of patients with biopsy-
proven HIVAN. 8 Although both studies 
may have been underpowered to detect a 
small diff erence in renal survival, it is also 
possible that diff erences were masked by 
the aggressive natural history of HIVAN. 
Overall, more than half of the subjects in 
the current study progressed to end-stage 
renal disease, and that proportion was 
slightly higher among those with two risk 
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alleles (59 vs. 48 % ). It is also possible that 
the association of  APOL1 variation with 
disease is more complicated than the 
recessive inheritance model supported by 
genome-wide analyses, 8 and the current 
study was not powered to distinguish 
between subjects with zero and one risk 
allele. As the authors suggest,  APOL1 
variation may also contribute susceptibil-
ity to HIVAN without playing a direct 
mechanistic role. 9 
 Interestingly, the strongest predictor of 
HIVAN progression in this cohort was 
diabetes, which was associated with a 
nearly 19-fold increase in the risk of end-
stage renal disease. Although this fi nding 
should be confi rmed in studies including 
a larger number of diabetic patients, it is 
conceivable that some of the infl amma-
tory or profi brotic pathways that contrib-
ute to diabetic nephropathy may accelerate 
the course of HIVAN. It is also notable 
that diabetes was more common among 
HIVAN patients with zero or one  APOL1 
risk allele, although the diff erence was not 
statistically signifi cant in this small cohort. 
A similar trend was noted for viral hepa-
titis co-infection and for history of illicit 
drug use, raising the possibility that other 
chronic kidney disease risk factors may 
serve as the  ‘ second hit ’ in HIV-positive 
people with zero or one  APOL1 risk allele. 
As the authors note, it is also possible that 
 MYH9 or other genes may contribute to 
the genetic susceptibility of people with 
zero or one  APOL1 risk allele. 
 Th e work of Atta and colleagues 9 con-
fi rms that  APOL1 risk variants account for 
much, but not all, of the susceptibility to 
HIVAN. Important work remains to 
determine APOL1 ’ s molecular function in 
kidney disease, and to determine what 
other genes and environmental factors 
contribute to FSGS susceptibility. With 
the continued growth of the HIV epi-
demic in sub-Saharan Africa, these fi nd-
ings also have important implications for 
global public health. While the  APOL1 
risk alleles are more frequent in West 
Africa, the G2 allele is also overrepre-
sented in other African populations. 4 
Given the tremendous genetic heteroge-
neity across Africa, the burden of HIVAN 
is likely to vary substantially. Although 
future studies should consider the local 
 APOL1 allele frequency in order to pro-
vide more accurate projections of HIVAN 
incidence, public-health offi  cials should 
be aware that these projections are likely 
to underestimate the true burden of 
disease. The study by Atta  et al. 9 also 
serves as a reminder of the devastating 
natural history of HIVAN, which appears 
to be substantially infl uenced not by dif-
ferences in underlying genetic susceptibil-
ity, but instead by the shared trigger for 
disease, HIV infection. Th us, eff orts to 
treat and prevent HIV infection in Africa 
and in other susceptible populations 
are an essential complement to ongoing 
investigation of HIVAN ’ s genetics and 
pathogenesis. 
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 Figure 1  |  Navigating a complicated intersection.  The  APOL1 and  MYH9 genes lie in a head-
to-head arrangement, and their genomic proximity makes it difficult to determine the relative 
contribution of variation in each gene to disease susceptibility. Early genome-wide mapping 
identified African ancestral single-nucleotide polymorphisms (SNPs) in  MYH9 that were strongly 
associated with focal segmental glomerulosclerosis (FSGS). Subsequent studies showed that 
these SNPs were only sentinels for  APOL1 SNPs with stronger association with FSGS. However, 
accumulating evidence now indicates that both genes may independently contribute to kidney 
disease susceptibility, and that although  APOL1 variation probably accounts for a majority of 
susceptibility to FSGS and HIV-associated nephropathy, it fails to explain a significant portion 
of disease. 
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